Temporal relations between atrial fibrillation and ischaemic stroke and their prognostic impact on mortality

DSpace/Manakin Repository

Temporal relations between atrial fibrillation and ischaemic stroke and their prognostic impact on mortality
 
Camen, Stephan; Ojeda, Francisco M.; Niiranen, Teemu; Gianfagna, Francesco; Vishram-Nielsen, Julie K.; Costanzo, Simona; Söderberg, Stefan; Vartiainen, Erkki; Donati, Maria Benedetta; Løchen, Maja Lisa; Pasterkamp, Gerard; Magnussen, Christina; Kee, Frank; Jousilahti, Pekka; Hughes, Maria; Kontto, Jukka; Mathiesen, Ellisiv B.; Koenig, Wolfgang; Palosaari, Tarja; Blankenberg, Stefan; De Gaetano, Giovanni; Jørgensen, Torben; Zeller, Tanja; Kuulasmaa, Kari; Linneberg, Allan; Salomaa, Veikko; Iacoviello, Licia; Schnabel, Renate B.
(2020) Europace, volume 22, issue 4, pp. 522 - 529
(Article)
Abstract
AIMS: Limited evidence is available on the temporal relationship between atrial fibrillation (AF) and ischaemic stroke and their impact on mortality in the community. We sought to understand the temporal relationship of AF and ischaemic stroke and to determine the sequence of disease onset in relation to mortality. METHODS AND ... read more
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Atrial fibrillation, Cohort study, Ischaemic stroke, Temporal relationship, Cardiology and Cardiovascular Medicine, Physiology (medical)
DOI: https://doi.org/10.1093/europace/euz312
ISSN: 1099-5129
Publisher: Oxford University Press
Note: Funding Information: Conflict of interest: S.Sö. has received lecture honoraria and advisory board fees from Actelion Pharmaceuticals Ltd outside the scope of the submitted work. V.S. has participated in a conference trip sponsored by Novo Nordisk and received a honorarium from the same source for participating in an advisory board meeting. He also has on-going research collaboration with Bayer Ltd (unrelated to the present study). W.K. reports personal fees from AstraZeneca, Novartis, DalCor, Kowa, Amgen, and Sanofi, grants and non-financial support from Roche Diagnostics, Beckmann, Singulex, and Abbott, all outside the scope of the submitted work. S.B. reports investigator-initiated grants from SIEMENS, Abbott Diagnostics, and Thermofisher, all outside the scope of the submitted work. R.B.S. has received lecture honoraria and advisory board fees from BMS/Pfizer outside the scope of the submitted work. V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also has ongoing research collaboration with Bayer AG. St.C., F.M.O., T.N., F.F., J.K.V.-N., Si.C., E.K., M.B.D., M.-J.L., G.P., C.M., F.K., P.J., M.H., J.K., E.B.M., G.d.G., T.J., T.Z., K.K., A.L., and L.I. all declare no conflict of interest. Funding Information: The BiomarCaRE Project is funded by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. HEALTH-F2-2011-278913. The activities of the MORGAM Data Center have been sustained by recent funding from European Union FP 7 project CHANCES (HEALTH-F3-2010-242244). The FINRISK surveys were mainly supported by budgetary funds of THL. Additional funding has been obtained from numerous non-profit foundations. V.S. (PI) has been supported by the Finnish Foundation for Cardiovascular Research and the Academy of Finland (139635). T.N. has been supported by the Finnish Medical Foundation, the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, and the Academy of Finland (321351). The DanMONICA cohorts at the Research Center for Prevention and Health were established over a period of 10 years and have been funded by numerous sources which have been acknowledged, where appropriate, in the original articles. The Moli-sani Project was partially supported by research grants from Pfizer Foundation (Rome, Italy), the Italian Ministry of University and Research (MIUR, Rome, Italy)'Programma Triennale di Ricerca, Decreto n.1588 and Instrumentation Laboratory, Milan, Italy. The Northern Sweden MONICA project was supported by Norrbotten and Vasterbotten County Councils. S.S. has been supported by the Swedish Heart'Lung Foundation (20140799, 20120631, 20100635), the County Council of Va'sterbotten (ALF, VLL-548791) and Umea University. The Troms' Study was supported by the UiT Arctic University of Norway, the municipality of Tromso, the Norwegian Research Council and the National Health Screening Service. T.Z. is supported by the German Center of Cardiovascular Reseasrch (Grant 81Z1710101, Partner site Project). We thank the participants and the staff of the cohorts for their continuing dedication and efforts. Conflict of interest: S.So. has received lecture honoraria and advisory board fees from Actelion Pharmaceuticals Ltd outside the scope of the submitted work. V.S. has participated in a conference trip sponsored by Novo Nordisk and received a honorarium from the same source for participating in an advisory board meeting. He also has ongoing research collaboration with Bayer Ltd (unrelated to the present study). W.K. reports personal fees from AstraZeneca, Novartis, DalCor, Kowa, Amgen, and Sanofi, grants and non-financial support from Roche Diagnostics, Beckmann, Singulex, and Abbott, all outside the scope of the submitted work. S.B. reports investigator-initiated grants from SIEMENS, Abbott Diagnostics, and Thermofisher, all outside the scope of the submitted work. R.B.S. has received lecture honoraria and advisory board fees from BMS/Pfizer outside the scope of the submitted work. V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also has ongoing research collaboration with Bayer AG. St.C., F.M.O., T.N., F.F., J.K.V.-N., Si.C., E.K., M.B.D., M.-J.L., G.P., C.M., F.K., P.J., M.H., J.K., E.B.M., G.d.G., T.J., T.Z., K.K., A.L., and L.I. all declare no conflict of interest. Funding Information: The BiomarCaRE Project is funded by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. HEALTH-F2-2011-278913. The activities of the MORGAM Data Center have been sustained by recent funding from European Union FP 7 project CHANCES (HEALTH-F3-2010-242244). The FINRISK surveys were mainly supported by budgetary funds of THL. Additional funding has been obtained from numerous non-profit foundations. V.S. (PI) has been supported by the Finnish Foundation for Cardiovascular Research and the Academy of Finland (139635). T.N. has been supported by the Finnish Medical Foundation, the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, and the Academy of Finland (321351). The DanMONICA cohorts at the Research Center for Prevention and Health were established over a period of 10 years and have been funded by numerous sources which have been acknowledged, where appropriate, in the original articles. The Moli-sani Project was partially supported by research grants from Pfizer Foundation (Rome, Italy), the Italian Ministry of University and Research (MIUR, Rome, Italy)–Programma Triennale di Ricerca, Decreto n.1588 and Instrumentation Laboratory, Milan, Italy. The Northern Sweden MONICA project was supported by Norrbotten and Västerbotten County Councils. S.S. has been supported by the Swedish Heart–Lung Foundation (20140799, 20120631, 20100635), the County Council of Västerbotten (ALF, VLL-548791) and Umeå University. The Tromsø Study was supported by the UiT Arctic University of Norway, the municipality of Tromsø, the Norwegian Research Council and the National Health Screening Service. T.Z. is supported by the German Center of Cardiovascular Reseasrch (Grant 81Z1710101, Partner site Project). Publisher Copyright: © 2019 Published on behalf of the European Society of Cardiology. All rights reserved.
(Peer reviewed)